Supplementary Figure 6 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

Expression of the protein biomarkers in pancreatic cancer tissues. A, Immunohistochemical analysis of REG1A: i) REG1A in poorly differentiated PDAC, ii) luminal REG1A in malignant glands. B, TFF1: i) heterogenous expression in cancer,, ii) luminal TFF1 in malignant gland. C, LYVE1 expression in the scattered lymphatic vessels i) in the muscle layer and ii) in the stroma surrounding malignant gland. D, The biomarker levels during monitoring of pancreatic adenocarcinoma patients: LYVE1, REG1A and TFF1 were measured using ELISA in urine samples collected before surgery and during the patient's follow up. Each point represents log-transformed ELISA values at a particular time point (x-axis).